WuXi Biologics (Cayman) Inc. provided earnings guidance for the six months ended June 30, 2022. The company expects that revenue of the Company for the six months ended June 30, 2022 will increase between 61% to 63%; the profit of the Company and the profit attributable to equity shareholders of the Company for the six months ended June 30, 2022 will increase between 36% to 38% and 35% to 37%, respectively; and after adjusting for share-based compensation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.3 HKD | +3.92% | +0.70% | -51.69% |
Mar. 27 | WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump | MT |
Mar. 27 | WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses | DJ |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.69% | 7.34B | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.49% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |
- Stock
- Equities
- Stock WuXi Biologics (Cayman) Inc. - Hong Kong S.E.
- News WuXi Biologics (Cayman) Inc.
- WuXi Biologics Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022